Placebo (n = 212) | CZPa (n = 851) | |
---|---|---|
Clinical characteristics | ||
Disease duration, yr, median (min–max) | 6.3 (0.3–49.0) | 5.43 (0.2–52.0) |
Tender joint count, mean (SD)b | 14.7 (6.6) | 14.7 (6.6) |
Swollen joint count, mean (SD)b | 11.1 (5.2) | 11.8 (5.6) |
DAS28(CRP), mean (SD) | 5.7 (0.9) | 5.7 (0.9) |
DAS28(ESR), mean (SD) | 6.4 (0.9) | 6.4 (0.9) |
Baseline patient-reported outcomes | ||
Fatigue Assessment Scale score, mean (SD) (0––10) | 6.4 (2.2) | 6.2 (2.2) |
Medical Outcomes Study Sleep Problem Index II score, mean (SD) (0–100) | 48.1 (19.9) | 47.6 (19.5) |
Pain VAS score, mean (SD) (0–100) | 62.3 (22.9) | 58.8 (23.3) |
PtGA VAS score, mean (SD) (0–100) | 61.6 (20.7) | 59.2 (22.1) |
RADAI-TS, mean (SD) (0–10) | 5.7 (1.9) | 5.6 (1.8) |
RAPID3, mean (SD) (0–30) | 15.5 (5.4) | 14.7 (5.5) |